Key result
Pegylated liposomal doxorubicin combined with gemcitabine achieved an overall response rate of 52% and a median overall survival of 16.1 months in metastatic breast cancer.
Why the study?
Does pegylated liposomal doxorubicin in combination with gemcitabine improve response rates in patients with metastatic breast cancer?
Does pegylated liposomal doxorubicin in combination with gemcitabine improve response rates in patients with metastatic breast cancer?
Pegylated liposomal doxorubicin combined with gemcitabine is an active and well-tolerated front-line therapeutic option for metastatic breast cancer, yielding a 52% overall response rate.
Answers are grounded in this paper and cite their sources.
Supports activity of pegylated liposomal doxorubicin plus gemcitabine in metastatic breast cancer; leaves open comparative efficacy versus standards.
PURPOSE: We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients were eligible if they had measurable disease, no prior chemotherapy for metastatic disease, and a performance status </= 2 on the Zubrod scale. Patients received pegylated liposomal doxorubicin 24 mg/m2 intravenously on day 1, plus gemcitabine 800 mg/m2 intravenously on days 1 and 8 of each 21-day cycle. RESULTS: Of 49 patients enrolled, 27 had received prior adjuvant chemotherapy (19 with an anthracycline). Prior median cumulative anthracycline dose was 240 mg/m2. In total, three complete responses and 21 partial responses were achieved in 46 assessable patients, for an overall response rate of 52% (95% confidence interval, 37% to 67%). Responses were observed in 11 (58%) of 19 patients with previous anthracycline exposure. Median response duration was 5.6 months, time to progression was 4.5 months, and overall survival was 16.1 months. Although the most common grade 3 to 4 toxicities were hematologic, few neutropenic complications resulted. The most frequent nonhematologic toxicities were nausea and vomiting, fatigue, stomatitis, and hand-foot syndrome. One patient previously treated with an anthracycline developed a transient decrease (21%) in the left ventricular ejection fraction, with cardiac function recovering within 2 months. CONCLUSION: Pegylated liposomal doxorubicin in combination with gemcitabine is active and well tolerated in patients with metastatic breast cancer. Median overall survival was 16.1 months, and approximately 78% of patients derived clinical benefit from treatment. This regimen represents a therapeutic option for patients receiving front-line therapy for their metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Rivera et al. (2003) studied Metastatic breast cancer (n=49). Pegylated liposomal doxorubicin in combination with gemcitabine was evaluated on overall response rate (95% CI 37-67). Pegylated liposomal doxorubicin combined with gemcitabine achieved an overall response rate of 52% and a median overall survival of 16.1 months in metastatic breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: